RAD — Radiopharm Theranostics Share News
0.000.00%
Last trade - 00:00- AU$15.95m
- AU$9.45m
- AU$2.77m
Brief: Radiopharm Theranostics Partners With Atomvie
Brief: Radiopharm Theranostics Launches American Depositary Receipt Program
Brief: Radiopharm Theranostics Increases Ownership In Radiopharm Ventures
Brief: Radiopharm Theranostics Receives $2 Mln Payment From Lantheus
Brief: Radiopharm Targets Nasdaq Listing By End Of 2024
Australia's Radiopharm Theranostics gains on FDA nod for imaging agent trial
Brief: Radiopharm Theranostics Receives FDA Ind Approval For Phase 2B Trial In Brain Metastases
Australia's Radiopharm Theranostics rises after first patient dosed in lung cancer trial
Brief: Radiopharm Theranostics Says End Of Agreements With Lind Partners
Brief: Radiopharm Theranostics Completes A$70 Million Placement
Australia's Radiopharm Theranostics hits near 2-month high on premium placement
Australia's Radiopharm Theranostics jumps on getting strategic investment
Brief: Radiopharm Theranostics Seeks Trading Halt
Brief: Radiopharm Theranostics Says HY Loss A$24.8 Million Versus Loss A$12.6 Million
Brief: Radiopharm Theranostics Secures Share Facility Agreement Of Up To A$12.5M
Brief: Radiopharm Theranostics Announces Entitlement Offer To Raise Around A$10 Mln
Australia's Radiopharm Theranostics hits 2-month low on discounted raise
Brief: Radiopharm Theranostics Says FDA Accepted Amended IND For Production And Distribution Of 68Ga-Trivehexin
Brief: Rad Receives Approval For Phase 1 Therapeutic Study Of Pdl1-Nanobody In Non-Small Cell Lung Cancer